Form 990 for tax year 2024

Totals

Total revenue

$54,466,208

Total expenses

$7,434,417

Contributions and grants received

$54,182,643

Grants paid

$2,181,501

Program service revenue

$0

Investment income

$283,565

Other revenue

$0

Total assets, end of year

$51,613,641

Total liabilities, end of year

$2,337,747

Net assets or fund balances, end of year

$49,275,894

Program services expenses (Part IX)

$6,322,259

Management and general expenses

$928,663

Fundraising expenses

$183,495

Program service expenses (Part III)

$6,322,259

Program services were 85.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2024

• 1. AI TOOL DEVELOPMENT AND OPEN-SOURCE INITIATIVE (TECHNOLOGICAL INNOVATION)(CONTINUED ON SCHEDULE O)IN 2024, EVERY CURE'S TECHNICAL TEAM BUILT A ROBUST, SCALABLE PLATFORM TO SYSTEMATICALLY IDENTIFY HIGH-POTENTIAL DRUG REPURPOSING OPPORTUNITIES. THE TEAM CURATED COMPREHENSIVE DRUG AND DISEASE LISTS BUILDING ON EXISTING ONTOLOGIES, ESTABLISHED A POWERFUL EXPERIMENTATION AND EVALUATION INFRASTRUCTURE, AND BEGAN THE INTEGRATION OF MULTIPLE PUBLIC AND PROPRIETARY BIOMEDICAL KNOWLEDGE GRAPHS INTO A HARMONIZED ARCHITECTURE. USING THIS FOUNDATION, THEY DEVELOPED AND STABILIZED A PIPELINE THAT ENABLED RAPID, LARGE-SCALE PREDICTION OF DRUG-DISEASE MATCHES, WHICH THEN GO FOR SYSTEMATIC REVIEW BY EVERY CURE'S MEDICAL TEAM. OVER THE COURSE OF THE YEAR, THE TEAM EXECUTED AND LOGGED EIGHT EXPERIMENTS TO VALIDATE AND REFINE MODEL PERFORMANCE, SIGNIFICANTLY ACCELERATING EXPERIMENTAL THROUGHPUT INTO 2025. WE ALSO OBTAINED RIGHTS TO SEVERAL PROPRIETARY DATASETS TO IMPROVE PERFORMANCE IN DIFFERENT STAGES IN THE PIPELINE.

  Expenses $4,332,726 · Grants $2,181,501

• 2. DRUG REPURPOSING RESEARCH AND DEVELOPMENT (SCIENTIFIC APPLICATION)(CONTINUED ON SCHEDULE O)EVERY CURE, INC. SAVES AND IMPROVES LIVES BY REPURPOSING DRUGS. DISCOVERY OF DRUG REPURPOSING OPPORTUNITIES OCCURS USING BOTH EXISTING KNOWLEDGE AND AI-GENERATED FINDINGS. DRUG REPURPOSING EFFORTS ENCOMPASS THE CORE SCIENTIFIC AND MEDICAL EFFORTS TO MOVE A DRUG REPURPOSING CONCEPT FROM DISCOVERY TO CLINICAL APPLICATION. ADVANCEMENT OF THE MOST PROMISING CANDIDATES MAY INCLUDE MANAGING PRE-CLINICAL STUDIES, REAL-WORLD EVIDENCE REVIEW AND CLINICAL TRIALS. IN 2024, EVERY CURE ESTABLISHED A WORLD CLASS MEDICAL TEAM, A TECHNICAL ADVISORY COUNCIL (TAC) AND A SCIENTIFIC ADVISORY COUNCIL (SAC) TO PROVIDE OVERSIGHT AND VALIDATE DISCOVERIES. THE TEAM ESTABLISHED BEST PRACTICE FOR VETTING REPURPOSING OPPORTUNITIES, LEADING TO THE IDENTIFICATION OF FOUR PROMISING REPURPOSED TREATMENTS ENDORSED BY THE SAC AS WELL AS IDENTIFICATION OF POTENTIAL THERAPEUTIC OPPORTUNITIES FOR LONG COVID. THE CANDIDATE DRUG REPURPOSING OPPORTUNITIES SPANNED CONDITIONS FROM A COMMON CANCER TO A RARE NEURODEVELOPMENTAL CONDITIONS. AS A RESULT OF THESE EFFORTS, MULTIPLE INDIVIDUALS SHARED STORIES OF HOW THEIR LIVES WERE SAVED AND IMPROVED BY REPURPOSED DRUGS.

  Expenses $1,844,784

• 3. EDUCATION AND AWARENESS-RAISING ON DRUG REPURPOSING(CONTINUED ON SCHEDULE O)EVERY CURE, INC. EDUCATES PHYSICIANS, RESEARCHERS, PATIENTS, POLICYMAKERS, AND THE GENERAL PUBLIC ABOUT THE POTENTIAL FOR DRUG REPURPOSING TO ACCELERATE CURES. EDUCATION AND OUTREACH ARE CENTRAL TO CREATING A SHIFT IN MEDICINE, WHERE EXISTING THERAPIES ARE FULLY LEVERAGED FOR DISEASES BEYOND THEIR ORIGINAL APPROVALS.SPECIFIC ACCOMPLISHMENTS INCLUDE: EDUCATIONAL PROGRAMS AND WORKSHOPS: ORGANIZED SCIENTIFIC CONVENINGS SUCH AS THE CHAN ZUCKERBERG INITIATIVE (CZI)-SUPPORTED WORKSHOP ON RARE DISEASE DRUG REPURPOSING, WHICH BROUGHT TOGETHER LEADING EXPERTS ACROSS ACADEMIA, INDUSTRY, AND GOVERNMENT TO SHARE KNOWLEDGE AND DEFINE COLLABORATIVE PATHWAYS. PROFESSIONAL OUTREACH: DISSEMINATED FINDINGS THROUGH PRESENTATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS, INVITED TALKS AT RESEARCH INSTITUTIONS, AND PUBLICATION OF EDUCATIONAL CONTENT IN PROFESSIONAL OUTLETS TO INCREASE AWARENESS AMONG PHYSICIANS AND SCIENTISTS. PATIENT AND PUBLIC ENGAGEMENT: LEVERAGED MEDIA EXPOSURE, SOCIAL MEDIA CAMPAIGNS, AND DIRECT PATIENT COMMUNITY ENGAGEMENT TO INCREASE UNDERSTANDING OF DRUG REPURPOSING OPPORTUNITIES, EMPOWERING PATIENTS TO DISCUSS POTENTIAL OPTIONS WITH THEIR PHYSICIANS. ROADMAP DEVELOPMENT: ADVANCED THE ROADMAP INITIATIVE, A FRAMEWORK FOR HOW TO SYSTEMATICALLY IDENTIFY AND VALIDATE REPURPOSING OPPORTUNITIES FOR RARE DISEASES, PROVIDING A REPLICABLE RESOURCE FOR THE FIELD. DIGITAL AWARENESS: REACHED MILLIONS THROUGH MEDIA FEATURES AND SOCIAL MEDIA, HIGHLIGHTING THE STORY OF DRUG REPURPOSING AND EVERY CURE'S MISSION, INCREASING VISIBILITY AND ENGAGEMENT WITH OUR WORK.THROUGH THESE ACTIVITIES, EVERY CURE HAS CREATED A FOUNDATION OF KNOWLEDGE AND AWARENESS THAT WILL HELP TO ACCELERATE THE PACE OF DRUG REPURPOSING ACROSS THE HEALTHCARE ECOSYSTEM.

  Expenses $144,749

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• UNIVERSITY OF NORTH CAROLINA

  $971,372

  UNC WILL CO-LEAD DEVELOPMENT OF THE INTEGRATION LAYER THAT CONNECTS DIVERSE DATASETS INTO A UNIFIED BIOMEDICAL KNOWLEDGE GRAPH. THEY WILL DEFINE ONTOLOGY STANDARDS, CONDUCT MANUAL CURATION, AND LEAD HARMONIZATION ACROSS DRUG, DISEASE, AND MOLECULAR DATA TYPES. THEIR ROLE ENSURES THE ROBOKOP AND MONARCH KNOWLEDGE GRAPHS AND PROPRIETARY DATASETS ARE SYSTEMATICALLY ALIGNED TO EVERY CURE'S COMPUTATIONAL INFRASTRUCTURE.

• THE SCRIPPS RESEARCH INSTITUTE

  $362,247

  SCRIPPS WILL INTEGRATE ITS BIOTHINGS EXPLORER PLATFORM INTO EVERY CURE'S KNOWLEDGE GRAPH, CONTRIBUTING APIS, DATA EVALUATION, AND ONTOLOGY MAPPING EXPERTISE. THEY WILL IDENTIFY PROPRIETARY DATASETS, EVALUATE THEIR UTILITY, AND REFINE INTEGRATION PROCESSES FOR CLINICAL AND PATIENT-LEVEL DATA. THEIR WORK STRENGTHENS INTEROPERABILITY AND ENSURES HIGH-VALUE BIOMEDICAL DATA IS CONNECTED ACROSS THE MATRIX PROJECT.

• INSTITUTE FOR SYSTEMS BIOLOGY

  $309,022

  ISB WILL CURATE, EVALUATE, AND INTEGRATE LARGE BIOMEDICAL DATASETS INTO EVERY CURE'S KNOWLEDGE GRAPH, FOCUSING ON DATA QUALITY AND ONTOLOGY HARMONIZATION. THEY WILL PERFORM MANUAL CURATION, CROSS-VALIDATION, AND DEVELOPMENT OF PROTOCOLS TO ENSURE RELIABLE DRUG, DISEASE, AND MOLECULAR ASSOCIATIONS. THEIR WORK ENSURES THE SPOKE DATABASE AND OTHER KEY SOURCES ARE INCORPORATED INTO A ROBUST COMPUTATIONAL FRAMEWORK FOR DRUG REPURPOSING.

• PENN STATE UNIVERSITY

  $303,699

  PENN STATE WILL LEAD THE DEVELOPMENT OF ADVANCED COMPUTATIONAL TOOLS, INCLUDING ALGORITHMS TO PREDICT DRUG REPURPOSING OPPORTUNITIES WITHIN THE KNOWLEDGE GRAPH. THEY WILL WORK ON DATA EXTRACTION, HARMONIZATION, AND MACHINE LEARNING MODEL DEVELOPMENT TO RANK CANDIDATE DRUGS. THEIR ROLE PROVIDES THE COMPUTATIONAL "ENGINE" THAT DRIVES PRIORITIZATION OF PROMISING THERAPIES.

• UNIVERSITY OF ALABAMA BIRMINGHAM

  $235,161

  UAB WILL CONTRIBUTE SPECIALIZED BIOMEDICAL DATA AND EXPERTISE IN INTEGRATING PATIENT-LEVEL, GENOMIC, AND CLINICAL DATASETS INTO THE KNOWLEDGE GRAPH. THEY WILL SUPPORT VALIDATION OF PREDICTED DRUG-DISEASE ASSOCIATIONS THROUGH COMPUTATIONAL AND EXPERIMENTAL METHODS. THEIR WORK ENSURES THE KNOWLEDGE GRAPH IS GROUNDED IN HIGH-QUALITY CLINICAL AND BIOLOGICAL EVIDENCE.

Provenance

Return type

form_990

Tax year

2024

Filed

27 October 2025

IRS schema version

2024v5.2

Source object

202513009349301626

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.